Table 2 Univariate survival analysis in 201 ovarian cancer patients

From: BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer

 Variable

 

Progression-free survival

Overall survival

Median, years (95% CI)

P value

Median, years (95% CI)

P value

A

Age

≤62.3 years

2.05 (1.47–2.63)

0.805

8.20 (5.63–10.78)

0.006

>62.3 years

1.81 (1.13–2.50)

 

3.35 (2.68–4.02)

 

FIGO stage

I/II

n.r.

<0.001

n.r.

<0.001

III/IV

1.48 (1.10–1.86)

 

3.62 (3.06–4.18)

 

Tumor grade

1/2

2.05 (1.23–2.87)

0.221

6.24 (2.82–9.67)

0.057

3

1.97 (1.16–2.78)

 

3.62 (3.03–4.21)

 

Residual disease

Macroscopically tumor-free

n.r.

<0.001

13.03 (n.r.)

<0.001

Any tumor residual

1.25 (1.06–1.44)

 

2.68 (1.83–3.53)

 

Histology

HGSOC

1.77 (1.35–2.18)

0.027

3.62 (3.13–4.12)

0.006

LGSOC

n.r.

 

n.r.

 

Endometrioid

5.98 (n.r.)

 

11.06 (n.r.)

 

Clear cell

1.81 (1.10-2.53)

 

2.72 (n.r.)

 

 Ovarian cancer type

Type I

n.r.

0.068

n.r.

0.022

Type II

1.91 (1.52–2.29)

 

3.82 (2.11–5.52)

 

 BRCA1 DNA methylation

No

2.00 (1.41–2.59)

0.850

4.54 (2.55–6.53)

0.521

Yes

1.95 (0.46–3.45)

 

4.89 (2.25–7.53)

 

 BRCA1 mRNA expression

Low

2.02 (1.38–2.65)

0.183

5.74 (3.63–7.85)

0.012

High

0.87 (0.00–1.82)

 

1.66 (0.00–5.00)

 

Subgroup analysis

 BRCA1 non-mutated

Low

2.06 (1.03–3.10)

0.169

4.89 (2.88–6.90)

0.023

High

0.87 (0.00–1.82)

 

1.67 (0.00–5.00)

 

 BRCA1 mutated

Low

2.00 (1.60–2.39)

–

8.20 (4.52–11.88)

–

High

–

 

–

 

 BRCA2 mRNA expression

Low

n.r.

0.004

n.r.

0.001

High

1.81 (1.41–2.22)

 

3.70 (2.78–4.62)

 

Subgroup analysis

 BRCA1 non-mutated

Low

n.r.

0.012

n.r.

0.002

High

1.65 (1.19–2.11)

 

3.62 (3.09–4.14)

 

 BRCA1 mutated

Low

7.49 (n.r.)

0.372

9.27 (n.r.)

0.463

High

1.98 (1.62–2.34)

 

6.03 (0.28–11.78)

 

B

 Age

≤62.3 years

1.98 (1.34–2.62)

0.590

6.86 (4.23–9.50)

0.012

>62.3 years

1.77 (1.27–2.26)

 

3.32 (2.63–4.01)

 

 FIGO stage

I/II

n.r.

<0.001

n.r.

<0.001

III/IV

1.47 (1.10–1.84)

 

3.43 (3.01–3.85)

 

 Tumor grade

2

1.90 (1.40–2.41)

0.398

5.74 (2.79–8.68)

0.177

3

1.95 (1.20–2.71)

 

3.55 (3.01–4.08)

 

 Residual disease

Macroscopically tumor-free

5.98 (n.r.)

<0.001

13.03 (n.r.)

<0.001

Any tumor residual

1.25 (1.06–1.44)

 

2.55 (1.58–3.51)

 

Histology

HGSOC

1.77 (1.35–2.18)

0.056

3.62 (3.13–4.12)

0.029

HGEOC

5.11 (n.r.)

 

8.94 (5.85–12.02)

 

HGCCOC

1.81 (1.10–2.53)

 

2.72 (n.r.)

 

BRCA1 DNA methylation

No

1.91 (1.35–2.47)

0.733

3.92 (2.09–5.76)

0.531

Yes

1.95 (0.51–3.40)

 

3.71 (1.65–5.77)

 

BRCA1 mRNA expression

Low

1.98 (1.34–2.62)

0.093

4.89 (2.74–7.04)

0.004

High

0.87 (0.02–1.72)

 

1.65 (0.68–2.63)

 

Subgroup analysis

 BRCA1 non-mutated

Low

1.95 (1.07–2.84)

0.094

3.94 (1.94–5.94)

0.011

High

0.87 (0.02–1.72)

 

1.65 (0.68–2.63)

 

 BRCA1 mutated

Low

2.00 (1.80–2.19)

–

8.20 (3.28–13.12)

–

High

–

 

–

 

BRCA2 mRNA expression

Low

n.r.

0.006

n.r.

0.002

High

1.81 (1.40–2.23)

 

3.62 (2.97–4.27)

 

Subgroup analysis

 BRCA1 non-mutated

Low

n.r.

0.022

n.r.

0.005

High

1.65 (1.19–2.11)

 

3.43 (2.96–3.90)

 

 BRCA1 mutated

Low

7.49 (n.r.)

0.326

12.58 (n.r.)

0.461

High

1.98 (1.62–2.34)

 

6.03 (0.28–11.78)

 

C

Age

≤62.3 years

1.81 (1.20–2.42)

0.650

5.74 (2.89–8.58)

0.035

>62.3 years

1.68 (1.07–2.29)

 

3.32 (2.74–3.89)

 

FIGO stage

I/II

n.r.

<0.001

7.78 (1.38–14.18)

0.049

III/IV

1.47 (1.09–1.84)

 

3.55 (3.15–3.94)

 

Tumor grade

1/2

1.65 (1.10–2.20)

0.519

3.82 (1.35–6.29)

0.257

3

1.95 (1.49–2.42)

 

3.55 (3.10–3.99)

 

Residual disease

Macroscopically tumor-free

3.57 (0.00–7.23)

<0.001

8.17 (2.26–14.08)

<0.001

Any tumor residual

1.26 (1.09–1.42)

 

2.94 (1.91–3.96)

 

BRCA1 DNA methylation

No

1.77 (1.33–2.21)

0.943

3.62 (3.07–4.17)

0.750

Yes

1.95 (0.92–2.99)

 

3.71 (2.02–5.40)

 

BRCA1 mRNA expression

Low

1.84 (1.51–2.17)

0.101

3.71 (2.73–4.69)

0.027

High

0.87 (0.14–1.60)

 

1.65 (0.42–2.88)

 

Subgroup analysis

 BRCA1 non-mutated

Low

1.68 (1.20–2.17)

0.117

3.62 (3.07–4.18)

0.051

High

0.87 (0.14–1.60)

 

1.65 (0.42–2.88)

 

 BRCA1 mutated

Low

1.98 (1.70–2.26))

–

6.03 (1.35–10.71)

–

High

–

 

–

 

BRCA2 mRNA expression

Low

n.r.

0.006

n.r.

0.001

High

1.67 (1.31–2.03)

 

3.39 (3.01–3.77)

 

Subgroup analysis

 BRCA1 non-mutated

Low

n.r.

0.016

n.r.

0.001

High

1.46 (1.06–1.87)

 

3.39 (2.87–3.91)

 

 BRCA1 mutated

Low

7.49 (n.r.)

0.531

12.58 (n.r.)

0.571

High

1.98 (1.69–2.27)

 

4.08 (0.00–9.78)

 
  1. The significance level (P) was determined by log-rank test
  2. HGCCOC high grade clear cell ovarian cancer, HGEOC high grade endometrioid ovarian cancer, HGSOC high grade serous ovarian cancer, LGSOC low grade serous ovarian cancer, n.r. not reached
  3. A: Progression free and overall survival in 201 ovarian cancer patients
  4. B: Subgroup analysis: progression-free and overall survival in 183 high grade OC patients
  5. C: Subgroup analysis: progression-free and overall survival in 129 high grade serous OC patients. The optimal cutoff points for BRCA1/2 mRNA expression were calculated by the Youden’s index for overall survival (BRCA1 expression: low/ high:</>90th %ile; BRCA2 expression: low/ high:</>21st %ile). Bold values indicates \(P \ \noexpand\lt\) 0.05
Back to article page